Yuri M Klyachkin1,2, Amr Idris1,2, Christopher B Rodell3, Himi Tripathi1,2, Shaojing Ye1,2, Prabha Nagareddy1,2, Ahmed Asfour1,2, Erhe Gao4, Rahul Annabathula1,2, Mariusz Ratajczak5, Jason A Burdick3, Ahmed Abdel-Latif6,7. 1. Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA. 2. Lexington VA Medical Center and Saha Cardiovascular Research Center, University of Kentucky, 741 South Limestone, BBSRB B349, Lexington, KY, 40536-0509, USA. 3. Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA. 4. The Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA. 5. Stem Cell Biology Institute, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA. 6. Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA. abdel-latif@uky.edu. 7. Lexington VA Medical Center and Saha Cardiovascular Research Center, University of Kentucky, 741 South Limestone, BBSRB B349, Lexington, KY, 40536-0509, USA. abdel-latif@uky.edu.
Abstract
BACKGROUND: Acute myocardial infarction (MI) and the ensuing ischemic heart disease are approaching epidemic state. Unfortunately, no definitive therapies are available and human regenerative therapies have conflicting results. Limited stem cell retention following intracoronary administration has reduced the clinical efficacy of this novel therapy. Cathelicidin related antimicrobial peptides (CRAMPs) enhance chemotactic responsiveness of BMSPCs to low SDF-1 gradients, suggesting a potential role in BMSPCs engraftment. Here, we assessed the therapeutic efficacy of CRAMPs in the context of BMSPCs recruitment and retention via intracardiac delivery of CRAMP-treated BMSPCs or CRAMP-releasing hydrogels (HG) post-AMI. METHODS: For cell transplantation experiments, mice were randomized into 3 groups: MI followed by injection of PBS, BMMNCs alone, and BMMNCs pre-incubated with CRAMP. During the in vivo HG studies, BM GFP chimera mice were randomized into 4 groups: MI followed by injection of HG alone, HG + SDF-1, HG + CRAMP, HG + SDF-1 + CRAMP. Changes in cardiac function at 5 weeks after MI were assessed using echocardiography. Angiogenesis was assessed using isolectin staining for capillary density. RESULTS: Mice treated with BMMNCs pre-incubated with CRAMP had smaller scars, enhanced cardiac recovery and less adverse remodeling. Histologically, this group had higher capillary density. Similarly, sustained CRAMP release from hydrogels enhanced the therapeutic effect of SDF-1, leading to enhanced functional recovery, smaller scar size and higher capillary density. CONCLUSION: Cathelicidins enhance BMMNC retention and recruitment after intramyocardial administration post-AMI resulting in improvements in heart physiology and recovery. Therapies employing these strategies may represent an attractive method for improving outcomes of regenerative therapies in human studies.
BACKGROUND:Acute myocardial infarction (MI) and the ensuing ischemic heart disease are approaching epidemic state. Unfortunately, no definitive therapies are available and human regenerative therapies have conflicting results. Limited stem cell retention following intracoronary administration has reduced the clinical efficacy of this novel therapy. Cathelicidin related antimicrobial peptides (CRAMPs) enhance chemotactic responsiveness of BMSPCs to low SDF-1 gradients, suggesting a potential role in BMSPCs engraftment. Here, we assessed the therapeutic efficacy of CRAMPs in the context of BMSPCs recruitment and retention via intracardiac delivery of CRAMP-treated BMSPCs or CRAMP-releasing hydrogels (HG) post-AMI. METHODS: For cell transplantation experiments, mice were randomized into 3 groups: MI followed by injection of PBS, BMMNCs alone, and BMMNCs pre-incubated with CRAMP. During the in vivo HG studies, BM GFP chimera mice were randomized into 4 groups: MI followed by injection of HG alone, HG + SDF-1, HG + CRAMP, HG + SDF-1 + CRAMP. Changes in cardiac function at 5 weeks after MI were assessed using echocardiography. Angiogenesis was assessed using isolectin staining for capillary density. RESULTS:Mice treated with BMMNCs pre-incubated with CRAMP had smaller scars, enhanced cardiac recovery and less adverse remodeling. Histologically, this group had higher capillary density. Similarly, sustained CRAMP release from hydrogels enhanced the therapeutic effect of SDF-1, leading to enhanced functional recovery, smaller scar size and higher capillary density. CONCLUSION: Cathelicidins enhance BMMNC retention and recruitment after intramyocardial administration post-AMI resulting in improvements in heart physiology and recovery. Therapies employing these strategies may represent an attractive method for improving outcomes of regenerative therapies in human studies.
Entities:
Keywords:
Bone marrow derived mononuclear cells (BMMNCs); Cathelicidin related antimicrobial peptide (CRAMP); LL-37; Myocardial infarction; Regeneration; Stem cells homing
Authors: Jasmine M F Wu; Ying-Chang Hsueh; Hui-Ju Ch'ang; Chwan-Yau Luo; Li-Wha Wu; Hiromitsu Nakauchi; Patrick C H Hsieh Journal: Circ Res Date: 2014-11-14 Impact factor: 17.367
Authors: G A McQuibban; G S Butler; J H Gong; L Bendall; C Power; I Clark-Lewis; C M Overall Journal: J Biol Chem Date: 2001-09-24 Impact factor: 5.157
Authors: Ahmed Abdel-Latif; Ewa K Zuba-Surma; Khaled M Ziada; Magdalena Kucia; Donald A Cohen; Alan M Kaplan; Gary Van Zant; Samy Selim; Susan S Smyth; Mariusz Z Ratajczak Journal: Exp Hematol Date: 2010-08-26 Impact factor: 3.084
Authors: Brendan P Purcell; Jeremy A Elser; Anbin Mu; Kenneth B Margulies; Jason A Burdick Journal: Biomaterials Date: 2012-07-24 Impact factor: 12.479
Authors: Christopher B Rodell; John W MacArthur; Shauna M Dorsey; Ryan J Wade; Leo L Wang; Y Joseph Woo; Jason A Burdick Journal: Adv Funct Mater Date: 2014-12-12 Impact factor: 18.808